

MISSISSIPPI Diabetes Data & Forecasts

State Total Population Forecasts	2015	2020	2025	2030
Entire Population	3,014,400	3,044,800	3,069,400	3,092,400
Prediabetes	857,100	894,300	928,500	936,700
Diagnosed diabetes	306,800	367,100	416,000	452,600
Undiagnosed diabetes	93,000	105,600	113,600	117,000
Total with diabetes (diagnosed and undiagnosed)	399,800	472,700	529,600	569,600
Complications:				
Visual impairment	50,300	58,400	64,300	67,900
Renal failure	730	840	920	970
Leg amputations	640	700	730	730
Annual deaths attributable to diabetes	3,300	3,770	4,060	4,180
Total annual cost (2015 dollars)	\$4.1 B	\$4.8 B	\$5.3 B	\$5.7 B
Annual medical costs	\$3.0 B	\$3.5 B	\$3.8 B	\$4.1 B
Annual nonmedical costs	\$1.1 B	\$1.3 B	\$1.5 B	\$1.6 B

State Senior Population Forecasts	2015	2020	2025	2030
Population 65 and older	433,400	499,200	573,500	634,100
Prediabetes	221,000	254,600	292,500	323,400
Diagnosed diabetes	81,900	94,400	108,400	119,800
Undiagnosed diabetes	30,400	34,900	40,100	44,400
Total with diabetes (diagnosed and undiagnosed)	112,300	129,300	148,500	164,200
Complications:				
Visual impairment	15,300	17,200	19,300	20,700
Renal failure	250	280	310	330
Leg amputations	190	200	210	220
Annual deaths attributable to diabetes	2,280	2,530	2,640	2,640
Total annual cost (2015 dollars)	\$1.4 B	\$1.7 B	\$1.9 B	\$2.1 B
Annual medical costs	\$1.3 B	\$1.6 B	\$1.8 B	\$2.0 B
Annual nonmedical costs	\$0.1 B	\$0.1 B	\$0.1 B	\$0.1 B

These forecasts are based on the latest available national diabetes data, including U.S Census Bureau population projections, the CDC National Diabetes Statistics Report, 2014, CDC diabetes morbidity trend reports, CDC's latest diabetes prevalence projections to 2050 and Dall, et al. "The Economic Burden of Elevated Blood Glucose Levels in 2012: Diagnosed and Undiagnosed Diabetes, Gestational Diabetes Mellitus, and Prediabetes," *Diabetes Care* 2014;37:3172-3179. These forecasts assume a steady, but conservative, reduction in the number of people with complications due to better awareness of the risks of diabetes, earlier screening and intervention, and more effective therapies.

For details and references on the Institute for Alternative Futures Diabetes 2030 Forecasting Model Methodology, visit www.altfutures.org/diabetes2030.

Research funded by Novo Nordisk Inc.